{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T22:29:48Z","timestamp":1761172188217,"version":"build-2065373602"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina de Familia. SEMERGEN"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.semerg.2021.09.009","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T23:24:37Z","timestamp":1636673077000},"page":"1-4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"S1","title":["Impacto de dapagliflozina en los factores de riesgo cardiovascular. M\u00e1s all\u00e1 del control de la glucemia"],"prefix":"10.1016","volume":"47","author":[{"given":"V.","family":"Pallar\u00e9s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Escobar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Egocheaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.C.","family":"Obaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semerg.2021.09.009_bib0070","article-title":"Utilizaci\u00f3n de los inhibidores de SGLT2 en atenci\u00f3n primaria: evidencia con dapagliflozina","author":"L\u00f3pez Simarro","year":"2019","journal-title":"Semergen"},{"key":"10.1016\/j.semerg.2021.09.009_bib0075","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40265-019-01148-3","article-title":"Dapagliflozin: A review in type 2 diabetes","volume":"79","author":"Dhillon","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.semerg.2021.09.009_bib0080","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"DECLARE\u2013TIMI 58 investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2021.09.009_bib0085","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2021.09.009_bib0090","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2021.09.009_bib0095","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semerg.2021.09.009_bib0100","unstructured":"World Health Organization. Global status report on non-communicable diseases 2010 [consultado Abr 2021]. Disponible en: http:\/\/www.who.int\/nmh\/publications\/ncd_report2010\/en\/"},{"key":"10.1016\/j.semerg.2021.09.009_bib0105","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.4103\/jfmpc.jfmpc_232_19","article-title":"Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure","volume":"8","author":"Pradhan","year":"2019","journal-title":"J Family Med Prim Care"},{"key":"10.1016\/j.semerg.2021.09.009_bib0110","unstructured":"Agencia Europea del Medicamento (European Medicines Agency; EMA). Forxiga\u00ae, Ficha t\u00e9cnica o resumen de las caracter\u00edsticas del producto. Actualizado el 9 de agosto de 2021 [consultado 5 Sep 2021]. Disponible en: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/forxiga-epar-product-information_en.pdf"},{"key":"10.1016\/j.semerg.2021.09.009_bib0115","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1080\/17512433.2017.1322507","article-title":"A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus","volume":"10","author":"Avogaro","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.semerg.2021.09.009_bib0120","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/dom.12189","article-title":"Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin","volume":"16","author":"Bolinder","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.semerg.2021.09.009_bib0125","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.semerg.2021.09.009_bib0130","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium\u2013glucose cotransporter 2 inhibitors for type 2 diabetes. A systematic review and metaanalysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med"}],"container-title":["Medicina de Familia. SEMERGEN"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359321002896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359321002896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:41:02Z","timestamp":1761108062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1138359321002896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":13,"alternative-id":["S1138359321002896"],"URL":"https:\/\/doi.org\/10.1016\/j.semerg.2021.09.009","relation":{},"ISSN":["1138-3593"],"issn-type":[{"type":"print","value":"1138-3593"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impacto de dapagliflozina en los factores de riesgo cardiovascular. M\u00e1s all\u00e1 del control de la glucemia","name":"articletitle","label":"Article Title"},{"value":"Medicina de Familia. SEMERGEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semerg.2021.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Sociedad Espa\u00f1ola de M\u00e9dicos de Atenci\u00f3n Primaria (SEMERGEN). Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}